AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Not yet recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06862206
- Locations
- 🇨🇳
Beijing Haidian Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chaoyang Hospital, Beijing, Beijing, China
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
Phase 2
Recruiting
- Conditions
- Obesity or Overweight
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT06862791
- Locations
- 🇨🇳
Research Site, Kaohsiung, Taiwan
REBECCA Real-world Early BrEast CanCer mAnagement
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 126
- Registration Number
- NCT06856343
- Locations
- 🇫🇷
Research Site, Valence Cedex 9, France
A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: AZD5004 film-coated tabletDrug: [14C]AZD5004 Solution for InfusionDrug: [14C]AZD5004 Oral Solution
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06857695
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
Not Applicable
Not yet recruiting
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Drug: Palivizumab 15 mg/kg
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT06851806
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Phase 2
Recruiting
- Conditions
- EndocrinologyDiabetes, Type IIObesity
- Interventions
- Drug: Placebo to match
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT06851858
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06846528
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06845813
- Locations
- 🇺🇸
Research Site, Tampa, Florida, United States
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Not yet recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT06842056
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06839872
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath